<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Assays used for diagnosing von Willebrand disease (VWD)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Assays used for diagnosing von Willebrand disease (VWD)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Assays used for diagnosing von Willebrand disease (VWD)</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Assay name</td> <td class="subtitle1">What it measures</td> <td class="subtitle1">Method</td> </tr> <tr> <td colspan="3">VWF activity</td> </tr> <tr> <td class="indent1">VWF activity: Platelet binding</td> <td>Ability of VWF to bind to:</td> <td>Quantitate binding of plasma VWF to:</td> </tr> <tr> <td class="indent2">VWF:RCo (ristocetin cofactor activity)</td> <td class="indent1">Fixed normal platelets in the presence of ristocetin</td> <td class="indent1">Platelets; assess agglutination using dilutions of plasma to quantitate VWF</td> </tr> <tr> <td class="indent2">VWF:GPIbR (binding to platelet glycoprotein Ib)</td> <td class="indent1">Recombinant GPIb in the presence of ristocetin</td> <td class="indent1">Recombinant GPIb using an ELISA plate or latex or magnetic beads</td> </tr> <tr> <td class="indent2">VWF:GPIbM (binding to a platelet glycoprotein Ib mutant)</td> <td class="indent1">Recombinant mutated "gain-of-function" GPIb (GPIbM) in the absence of ristocetin</td> <td class="indent1">Recombinant GPIbM using an ELISA plate or latex or magnetic beads</td> </tr> <tr> <td class="indent2">Binding to a monoclonal antibody to the GPIb site)</td> <td class="indent1">Binding of a specific monoclonal antibody to the VWF binding site for GPIb</td> <td class="indent1">Antibody that is specific for the GPIb binding site in VWF</td> </tr> <tr class="divider_bottom"> <td class="indent1">VWF activity: Collagen binding (VWF:CB)</td> <td>VWF binding to collagen</td> <td>Binding of patient plasma VWF to collagen-coated plates in an ELISA assay (usually type I or type III collagen)</td> </tr> <tr class="divider_bottom"> <td>VWF antigen (VWF:Ag)</td> <td>VWF protein concentration measured by immunologic assays (does not imply functional activity)</td> <td>Immunologic assay using ELISA, RIA, or latex beads</td> </tr> <tr class="divider_bottom"> <td>VWF multimer analysis</td> <td>Distribution of VWF multimers as visualized in gels</td> <td>Electrophoresis in low concentration agarose gel and visualization using a monospecific antibody to VWF</td> </tr> <tr class="divider_bottom"> <td>Ristocetin-induced platelet aggregation (RIPA)</td> <td>Ability of patient's VWF to bind to platelets in the presence of suboptimal concentrations of ristocetin</td> <td>Platelet aggregation using patient's platelet-rich plasma and low concentrations of ristocetin (less than required in VWF:RCo)</td> </tr> <tr class="divider_bottom"> <td>VWF activity:VWF antigen ratio (VWF:Act/VWF:Ag)</td> <td>Comparison of functional activity of VWF with its protein concentration</td> <td>Ratio of measured levels of VWF:Act to VWF:Ag (a ratio of &lt;0.7 suggests type 2A, 2B, or 2M)</td> </tr> <tr> <td>Factor VIII activity:VWF:Ag ratio (FVIII/VWF:Ag)</td> <td>Comparison of factor VIII activity to VWF antigen</td> <td>Ratio of measured levels of FVIII to VWF:Ag (a low level suggests type 2N)</td> </tr> </tbody></table></div><div class="graphic_lgnd">von Willebrand factor is a multimeric glycoprotein that promotes platelet adhesion to collagen and platelet aggregation. VWF also acts as a carrier protein for coagulation factor VIII in plasma. Ristocetin is an antibiotic (no longer in clinical use) that induces VWF binding to platelet glycoprotein Ib (GPIb), which in turn causes platelets to aggregate. Refer to UpToDate for information on how these tests are used and interpreted in the patient evaluation.</div><div class="graphic_footnotes">VWD: von Willebrand disease; 
	VWF: von Willebrand factor; 
	ELISA: enzyme-linked immunosorbent assay; 
	RIA: radioimmunoassay.</div><div class="graphic_reference">Adapted from: The National Heart, Lung, and Blood Institute. The Diagnosis, Evaluation, and Management of Von Willebrand Disease. Bethesda, MD: National Institutes of Health Publication 08-5832, December 2007.</div><div id="graphicVersion">Graphic 73391 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
